Asset Details
Do you wish to reserve the book?
Economic impact of a genetic test for cisplatin-induced ototoxicity
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Economic impact of a genetic test for cisplatin-induced ototoxicity
Do you wish to request the book?
Economic impact of a genetic test for cisplatin-induced ototoxicity
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Economic impact of a genetic test for cisplatin-induced ototoxicity
2012
Overview
Cisplatin is a widely used chemotherapy drug in the treatment of pediatric solid tumors, but it is associated with significant rates of ototoxicity (medication-induced hearing loss). A genetic test has recently been developed that can help predict the likelihood that a cisplatin-treated pediatric patient will develop ototoxicity. This study estimates the potential economic impact of this test. Assuming that an alternative, non-preferred, medication to cisplatin exists that it is as efficacious as cisplatin but without the risk of hearing loss, and that the alternative treatment is no more expensive than current practice, we have estimated that administering this genetic test to every pediatric cancer patient for whom cisplatin is first-line therapy could potentially avoid an average of $71 168 in societal costs per tested patient. This translates into a potential present value savings of over $2.4 million annually in British Columbia and over $19.6 million in Canada.
Publisher
Nature Publishing Group UK,Nature Publishing Group
Subject
/ Adult
/ Antineoplastic Agents - adverse effects
/ Antineoplastic Agents - economics
/ Biomedical and Life Sciences
/ Canada
/ Child
/ Complications and side effects
/ Drugs
/ Genetic Predisposition to Disease
/ Hearing Loss - chemically induced
/ Hearing Loss - prevention & control
/ Humans
/ Oncology
/ Patients
